FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($1.50) per share for the year, up from their previous estimate of ($2.25). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($3.25) EPS and FY2028 earnings at ($2.95) EPS.

Several other research analysts have also recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Leerink Partners started coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Finally, Chardan Capital began coverage on Stoke Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $24.00 target price on the stock. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Trading Up 4.6 %

Shares of STOK opened at $10.99 on Friday. The stock has a 50 day simple moving average of $11.08 and a 200 day simple moving average of $12.72. Stoke Therapeutics has a 52-week low of $4.09 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Insiders Place Their Bets

In related news, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares in the company, valued at approximately $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 2,586 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $33,592.14. Following the transaction, the insider now directly owns 44,746 shares in the company, valued at approximately $581,250.54. This trade represents a 5.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock valued at $809,421 in the last 90 days. 11.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. acquired a new stake in Stoke Therapeutics during the 4th quarter valued at $124,000. Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter worth about $160,000. The Manufacturers Life Insurance Company lifted its stake in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares during the last quarter. Mesirow Financial Investment Management Inc. bought a new position in Stoke Therapeutics in the 3rd quarter valued at about $192,000. Finally, Rhumbline Advisers lifted its position in Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after acquiring an additional 2,787 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.